Clinical utility of available methods for determining platelet function

Cardiology

Volumn 92, Issue 4, 1999, Pages 240-247

  McKenzie, Marcus E ^a   Gurbel, Paul A ^a   Levine, Douglas J ^a   Serebruany, Victor L ^a  

^a SINAI HOSPITAL OF BALTIMORE   (United States)

Author keywords

Analyzers; Clinical utility; Platelet function

Indexed keywords

ANTITHROMBOCYTIC AGENT;

BLOOD CLOT; DEVICE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FLOW CYTOMETRY; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

EID: 0033513303     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000006981     Document Type: Review

References (61)

1. Kleinman NS, Lincoff AM, Ohman EM, Harrington RA: Glycoprotein IIb/IIIa inhibitors in acute coronary syndrome: Pathophysiologic foundation and clinical findings. Am Heart J 1998;136(4 Pt 2 Su):S32-S42.
2. Kugelmass AD: Inhibitors of the platelet GP IIb-IIIa function in the treatment of acute coronary syndromes. Curr Opin Hematol 1997;4: 301-305.
3. Kereiakes DJ: Oral blockade of the platelet glycoprotein IIb/IIIa receptor: Fact or fancy? Am Heart J 1999;138(1 Pt 2):39-46.
4. Rodgers GM: Overview of platelet physiology and laboratory evaluation of platelet function. Clin Obstet Gynecol 1999;42:349-359.
5. Chong BH, Burgess J, Ismail F: The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993;69:344-350.
6. Becker RC: Thrombosis and the role of the platelet. Am J Cardiol 1999;83:3E-6E.
7. Born GVR: Qualitative investigations into the aggregation of blood platelets. J Physiol (Lond) 1962;67:162.
8. Mascelli MA, Worley S, Veriabo NJ, Lance ET, Mack S, Schaible T, Weisman HF, Jordan RE: Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997;96:3860-3866.
9. Satoh K, Ozaki Y, Kume S: Detection of platelet aggregates using light scattering. Rinsho Byori 1995;43:426-431.
10. Salmon DM: Optimisation of platelet aggregometry utilising micotitreplate technology and integrated software. Thromb Res 1996;84: 213-216.
11. Nielsen HK, Christensen NJ, Husted SE: A new automated technique for platelet aggregation measurement. Scand J Clin Lab Invest 1984;44:217-222.
12. Elwood PC, Beswick AD, Sharp DS, Yarnell JW, Rogers S, Renaud S: Whole blood impedance platelet aggregometry and ischemic heart disease. The Caerphilly Collaborative Heart Disease Study. Arteriosclerosis 1990;10:1032-1036.
13. Breddin HK, Lippold R, Bittner M, Kirchmaier CM, Krzywanek HJ, Michaelis J: Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study. Haemostatic parameters as risk factors in healthy volunteers. Atherosclerosis 1999;144:211-219.
14. The EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
15. Harrington RA, Kleinman NS, Granger CB, Ohman EM, Berkowitz SD: Relation between inhibition of platelet aggregation and clinical outcomes. Am Heart J 1998;136:s43-s50.
16. Mammen EF, Alshameeri RS, Comp PC: Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995;21(suppl 2):113-121.
17. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA: Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost 1995;21(suppl 2):106-112.
18. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ: PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202.
19. Rodgers RPC, Levin J: A critical appraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20.
20. Kottke-Marchant K, Powers J, Brooks L: Inhibition of platelet function with ReoPro(abciximab) detected by the platelet function analyzer (PFA-100) in patients undergoing coronary angioplasty (PTCA). Blood 1997;90(suppl 1): 70b.
21. Di Paola J, Federici AB, Mannucci PM, Canciani MT, Kritzik M, Kunicki TJ, Nugent D: Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. Blood 1999;93:3578-3582.
22. Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D: Screening for von Willebrand disease with a new analyzer using high shear stress: A study of 60 cases. Blood 1998;91:1325-1331.
23. Rand ML, Carcao MD, Blanchette VS: Use of the PFA-100 in the assessment of primary, platelet-related hemostasis in a pediatric setting. Semin Thromb Hemost 1998;24:523-529.
24. Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ: Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinolysis 1999;10:25-31.
25. Mody M, Lazarus AH, Semple JW, Freedman J: Preanalytical requirements for flow cytometric evaluation of platelet activation: Choice of anticoagulant. Transfus Med 1999;9:147-154.
26. Rinder HM: Platelet function testing by flow cytometry. Clin Lab Sci 1998;11:365-372.
27. Kohmura C, Hayashi Y, Ikeda H: Detection of activated platelets by flow cytometry. Rinsho Byori 1999;47:447-452.
28. Quinn M, Deering A, Stewart M, Cox D, Foley B, Fitzgerald D: Quantifying GPIIb/IIIa receptor binding using 2 monoclonal antibodies: Discriminating abciximab and small molecular weight antagonists. Circulation 1999;99:2231-2238.
29. Xiao Z, Theroux P, Frojmovic M: Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GPIIb/IIIa receptor. Thromb Haemost 1999;81:281-285.
30. Bihour C, Durrieu-Jais C, Macchi L, Poujol C, Coste P, Besse P, Nurden P, Nurden AT: Expression of markers of platelet activation and the interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999;19: 212-219.
31. Holmes MB, Sobel BE, Schneider DJ: Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999;84: 203-207.
32. Holmes MB, Sobel BE, Howard DB, Schneider DJ: Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999;95:75-82.
33. Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, Fox KM: Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, P1A2. Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 1999;20:742-747.
34. Tarnok A, Mahnke A, Muller M, Zotz RJ: Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. Cytometry 1999;38:30-39.
35. Beythien C, Gutensohn K, Bau J, Hamm CW, Kuhnl P, Meinertz T, Terres W: Influences of stent length and heparin coating on platelet activation: A flow cytometric analysis in a pulsed floating model. Thromb Res 1999;94: 79-86.
36. O'Connor CM, Gurbel PA, Serebruany VL: Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol 1999;83:1345-1349.
37. Zeller JA, Tschoepe D, Kessler C: Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost 1999;81:373-377.
38. Carr ME Jr: Measurement of platelet force: The Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995;9:312-314, 316-318, 320.
39. Carr ME, Zekert SL: Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: Report of a case. Blood Coagul Fibrinolysis 1991;2:303-308.
40. Greilich PE, Carr ME, Carr SL, Chang AS: Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage. Anesth Analg 1995;80:459-465.
41. Carr ME, Carr SL, Hantgan RR, Braaten J: Glycoprotein IIb/IIIa blockade inhibits platelet mediated force development and reduces gel elastic modulus. Thromb Haemost 1995;73: 499-505.
42. Greilich PE, Alving BM, Longnecker D, Carr ME Jr, Whitten CW, Chang AS, Reid TJ: Nearsite monitoring of the antiplatelet drug abciximab using the Hemodyne analyzer and modified thromboelastograph. J Cardiothorac Vasc Anesth 1999;13:58-64.
43. Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS: Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
44. Kereiakes DJ, Mueller M, Howard W, Lacock P, Anderson LC, Broderick TM, Roth EM, Abbottsmith CW: Efficacy of abciximab induced platelet blockade using a rapid point of care assay. J Thromb Thrombolysis 1999;7: 265-276.
45. Li CK, Hoffmann TJ, Hsieh PY, Malik S, Watson WC: The Xylum clot signature analyzer: A dynamic flow system that simulates vascular injury. Thromb Res 1998;92(suppl 2):67-77.
46. Chandler WL, Schmer G: Evaluation of a new dynamic viscometer for measuring the viscosity of whole blood and plasma. Clin Chem 1986; 32:505-507.
47. Horlocker TT, Schroeder DR: Effect of age, gender, and platelet count on Sonoclot coagulation analysis in patients undergoing orthopedic operations. Mayo Clin Proc 1997;72:214-219.
48. Samra SK, Harrison RL, Bee DE, Valero V: A study of aspirin induced changes in bleeding time, platelet aggregation, and Sonoclot coagulation analysis in human. Ann Clin Lab Sci 1991;21:315-327.
49. Miyashita T, Kuro M: Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg 1998;87:1228-1233.
50. Stern MP, DeVos-Doyle K, Viguera MG, Lajos TZ: Evaluation of postcardiopulmonary bypass Sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs. J Cardiothorac Anesth 1989;3:730-733.
51. Pivalizza EG, Abramson DC, Harvey A: Perioperative hypercoagulability in uremic patients: A viscoelastic study. J Clin Anesth 1997; 9:442-445.
52. Francis JL, Francis DA, Gunathilagan GJ: Assessment of hypercoagulability in patients with cancer using the Sonoclot analyzer and thromboelastography. Thromb Res 1994;74:335-346.
53. Shih RL, Cherng YG, Chao A, Chen JT, Tsai AL, Liu CC: Prediction of bleeding diathesis in patients undergoing cardiopulmonary bypass during cardiac surgery: Viscoelastic measures versus routine coagulation test. Acta Aneasthesiol Sin 1997;35:133-139.
54. Wenker O, Wojciechowski Z, Sheinbaum R, Zisman E: Thromboelastography. Internet J Anesthesiol 1997;1(3)(http://www.ispub.com/ journals/IJA/Vol1N3/teg.htm).
55. Cherng YG, Chao A, Shih RL, Lin CS, Chan WH, Huang CH, Tsai SK: Preoperative evaluation and postoperative prediction of hemostatic function with thromboelastography in patients undergoing redo cardiac surgery. Acta Anaesthesiol Sin 1998;36:179-186.
56. Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA: Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-319.
57. Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Starzl TE, Winter PM: Intraoperative changes in blood coagulation and thromboelastographic monitoring in liver transplantation. Anesth Analg 1985;64: 888-896.
58. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK: Thromboelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998;43: 267-271.
59. Ben-Ari Z, Panagou M, Patch D, Bates S, Osman E, Pasi J, Burroughs A: Hypercoagulability in patients with primary biliary cirrhosis and primary sclerosing cholangitis evaluated by thromboelastography. J Hepatol 1997;26: 554-559.
60. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD: Monitoring platelet glycoprolein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Mod 1997;130:401-411.
61. Greilich PE, Alving BM, O'Neill KL, Chang AS, Reid TJ: A modified thromboelastographic method for monitoring c7E3 Fab in heparinized patients. Anesth Analg 1997;84:31-38.